Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7290743 | 0.89 | OPRD1 (0.46) | OPRD1OPRM1OPRK1ALDH1A1MAPT | |
| SCHEMBL7290758 | 0.89 | OPRD1 (0.46) | OPRD1OPRM1OPRK1ALDH1A1MAPT | |
| SCHEMBL30964325 | 0.88 | FURIN (0.44) | OPRD1OPRM1OPRK1 | |
| SCHEMBL31518662 | 0.86 | ALDH1A1 (0.49) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL30964330 | 0.83 | SLC15A2 (0.45) | — | |
| SCHEMBL11127918 | 0.83 | ALDH1A1 (0.49) | OPRD1OPRM1OPRK1ALDH1A1MAPT | |
| SCHEMBL30964328 | 0.83 | GRIN2D (0.43) | — | |
| SCHEMBL6367826 | 0.83 | OPRM1 (0.44) | OPRD1OPRM1OPRK1ALDH1A1MAPT | |
| SCHEMBL29989920 | 0.83 | OPRD1 (0.48) | OPRD1OPRM1OPRK1ALDH1A1MAPT | |
| SCHEMBL6367814 | 0.83 | OPRM1 (0.44) | OPRD1OPRM1OPRK1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199698-A1 | PEPTIDE AMPHIPHILE COMPOSITIONS AND METHODS OF USE THEREOF | Endomimetics LLC | 2024-06-20 | — | — | US | claimed |
| US-20240218017-A1 | PEPTIDE AMPHIPHILES WITH MODIFIED DEGRADING SEQUENCES AND METHODS OF USE THEREOF | Endomimetics LLC | 2024-07-04 | — | — | US | disclosed |
| US-20240199698-A1 | PEPTIDE AMPHIPHILE COMPOSITIONS AND METHODS OF USE THEREOF | Endomimetics LLC | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218017-A1 | PEPTIDE AMPHIPHILES WITH MODIFIED DEGRADING SEQUENCES AND METHODS OF USE THEREOF | ABHD16A, LIPG, POLQ | OPRD1 3240/4885OPRM1 3166/4885OPRK1 3479/4885 |
| US-20240199698-A1 | PEPTIDE AMPHIPHILE COMPOSITIONS AND METHODS OF USE THEREOF | PLD4, NGLY1, VIP | OPRD1 1936/4885OPRM1 2617/4885OPRK1 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.